Stem Cell Assay Market Size, Share, Trends | 2032

Report Description

Stem Cell Assay Market Outlook 2032

The global stem cell assay market size was USD 2.1 Billion in 2023 and is projected to reach USD 7.63 Billion by 2032, expanding at a CAGR of 17.5% during 2024–2032. The market growth is attributed to the rising demand for cell-based assays in drug discovery, growing demand for personalized medicine, and advancements in assay technologies.

Rising innovation in biomedical research, drug discovery, and regenerative medicine is boosting the market. Stem cell assays play a crucial role in evaluating the behavior, characteristics, and therapeutic potential of stem cells, which are increasingly recognized for their remarkable regenerative properties and ability to differentiate various cell types. Additionally, these cells accelerate the discovery and development of regenerative therapies for various degenerative diseases, including cardiovascular disorders, neurodegenerative diseases, and orthopedic conditions.

Increasing investments in stem cell research and rising prevalence of chronic diseases are expected to propel the stem cell assay market in the coming years. Stem cell assays find wide-ranging applications across pharmaceutical and biotechnology companies, academic and research institutions, and clinical laboratories. They are utilized for drug screening and toxicity testing, disease modeling, understanding developmental processes, and identifying novel therapeutic targets.

The key market players are actively engaged in developing innovative stem cell assay platforms, kits, and reagents to meet the evolving needs of researchers and clinicians. Moreover, collaborations between industry players, academic institutions, and government agencies are fostering advancements in stem cell technologies and driving market expansion. Moreover, the global stem cell assay market presents lucrative opportunities for stakeholders, with the potential to revolutionize healthcare and contribute to the development of novel therapies for unmet medical needs. For instance,

• In March 2022, according to the Australian Bureau of Statistics, an independent statutory agency of the Government of Australia, nearly 46% (around 11.6 Million) of the population of all ages had one or more chronic diseases.
  

  Get Free Sample Report
  

Impact of Artificial Intelligence (AI) in the Stem Cell Assay Market

Artificial intelligence (AI) is playing a crucial role in the stem cell assay market. AI algorithms analyze large datasets to identify personalized treatment options based on an individual’s genetic makeup and disease profile. In stem cell research, AI helps tailor therapies by predicting patient responses and optimizing treatment protocols. Organoids (miniature organs grown in vitro) and tissue engineering, benefit from AI-driven modeling and optimization, as AI assists in designing and improving organoids for drug testing, disease modeling, and regenerative medicine.

The impact of AI in the stem cell assay market is transformative, revolutionizing the way researchers conduct experiments, analyze data, and derive insights. AI contributes to the growth and advancements of stem cell assays by enhancing efficiency, precision, and our understanding of stem cell biology. AI-powered tools and algorithms enhance stem cell assays' efficiency, accuracy, and scalability, enabling researchers to accelerate drug discovery, disease modeling, and therapeutic development. For instance,

• In August 2022, Atomwise and Sanofi established an exclusive research collaboration to leverage Atomwise's AtomNet platform for computational drug discovery across up to five targets. This AI-driven approach offers a structured and efficient alternative to traditional serendipitous methods, employing deep learning for rapid exploration of Atomwise's vast compound library.

AI algorithms learn from stem cell data, enabling improved predictions and decision-making. Machine learning models identify patterns, predict cell behavior, and optimize experimental conditions. AI accelerates the discovery of novel stem cell markers, drug candidates, and therapeutic targets.

AI assists in assessing safety and efficacy during drug development. It aids in addressing ethical concerns related to stem cell research and therapy. For example, Cellino Biotech combines stem cell biology, machine learning, and laser physics to automate stem cell manufacturing.

Stem Cell Assay Market Dynamics

Get Free Sample Report

Major Drivers

Rising prevalence of chronic diseases is driving the stem cell assay market. Increasing incidence of chronic diseases, such as cancer, cardiovascular disorders, and neurological conditions, fuels the need for innovative stem cell-based therapies, thus boosting the demand for stem cell assays. For instance,

• In June 2023, a report published by the American Diabetes Association states that stem cell-derived islet cell therapy demonstrates promising outcomes for achieving insulin independence among individuals diagnosed with Type 1 Diabetes. The research reveals that fully differentiated islet cells derived from stem cells effectively restore endogenous insulin secretion and lead to improved glycemic control in patients living with Type 1 Diabetes.

Increasing awareness of the therapeutic potency of stem cells is driving the demand for stem cell assays in the market. Growing acceptance of current stem cell culture technology and rising incidence of cancer and cardiovascular diseases contribute to market expansion.

Increasing Investments in stem cell research is expected to propel the market during the forecast period. Growing funding from government bodies, private organizations, and research institutions for stem cell research is driving the demand for stem cell assays.

Advancements in assay technologies are anticipated to fuel the market during the forecast period. Ongoing technological advancements, such as high-throughput screening methods, 3D cell culture techniques, and automation, enhance the efficiency, accuracy, and scalability of stem cell assays, thus driving the market.

Expanding applications in drug discovery and toxicity testing are fueling the market. Stem cell assays are increasingly adopted by pharmaceutical and biotechnology companies for drug screening, toxicity assessment, and target identification thus, driving the market.

Existing Restraints

Ethical and regulatory challenges are restraining the stem cell assay market. Ethical concerns surrounding the use of embryonic stem cells and regulatory restrictions on stem cell research and therapy development pose challenges the market, particularly in certain regions.

Technical complexities and standardization issues are expected to hamper the market in the coming years. The technical complexity of stem cell assays, variability in cell culture conditions, and the lack of standardized protocols hinder assay reproducibility and reliability, impacting the market.

High cost of assay development and implementation is expected to create challenges in the market. The high cost associated with the development, validation, implementation of stem cell assays, and the high need for specialized equipment and expertise, limit accessibility, especially for small research institutions and laboratories.

Emerging Opportunities

Growing demand for personalized medicine is expected to create opportunities in the market during the projected period. The shift toward personalized medicine is driven by genetic insights and precision medicine approaches, which creates opportunities for stem cell assays to facilitate patient-specific drug screening and disease modeling.

Emerging applications in regenerative medicine are expected to generate lucrative opportunities in the market. Growing interest in regenerative medicine and cell therapy for stem cell assays supports the development of novel regenerative therapies and tissue engineering solutions.

Expansion of 3D cell culture technologies projects new opportunities for the market. The increasing adoption of 3D cell culture models and organoid systems in stem cell research opens new avenues for stem cell assay development, enabling physiologically relevant disease modeling and drug screening.

Growing focus on disease modeling and precision medicine is propelling the market. Growing emphasis on disease modeling, personalized medicine, and predictive toxicology creates opportunities for stem cell assays to contribute to disease understanding, patient stratification, and drug development strategies.

Scope of the Stem Cell Assay Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Stem Cell Assay Market Segment Insights

Assay Type Segment Analysis

Based on assay type, the stem cell assay market is divided into viability/cytotoxicity assays, apoptosis assays, proliferation assays, isolation & purification assays, cell identification assays, and others. The viability/cytotoxicity assays segment held a major share of the market in 2023 owing to the increasing adoption of assays in pharmacology & toxicology. These assays determine the number of dead and live cells in a culture medium. They are used to assess the physiological and physical well-being of cells in response to medicinal treatments, chemical agents, and other situations, that decide fine culture for cell growth.

Get Free Sample Report

Cell Type Segment Analysis

On the basis of cell type, the global market is segregated into induced pluripotent stem cells, adult stem cells, umbilical cord stem cells, neural stem cells, and others. The induced pluripotent stem cells (iPSCs) segment held the largest share of the market in 2023, due to their versatility and a wide range of applications. Induced pluripotent stem cells are reprogrammed adult cells that possess the ability to differentiate into various cell types, making them valuable tools for disease modeling, drug discovery, and regenerative medicine applications.

Their potential to generate patient-specific cell lines for personalized therapies and their ability to overcome ethical concerns associated with embryonic stem cells contribute to their prominence in the stem cell assay market.

Product Type Segment Analysis

Based on product type, the stem cell assay market is segmented into instruments, flow cytometers, automated cell counters, equipment & kits, and services. The instruments segment led the market, in terms of revenue in 2023, due to the increasing number of stem cell research activities and the rising technological innovations in stem cell instruments.

Get Free Sample Report

Application Segment Analysis

On the basis of application, the market is divided into drug discovery & development, regenerative medicine & therapy development, disease modeling, clinical research, and others. The regenerative medicine & therapy development segment generate a major revenue share of the market in 2023, due to the growing demand for stem cells in the research & development of different types of cell therapies. Researchers are exploring the potential of stem cells in developing new therapies and understanding disease mechanisms. For instance,

• In July 2021, Agilent Technologies expanded its footprint in the testing and diagnostic market in Europe by advancing the utilization of PD-L1 IHC 22C3 pharmDx for trials involving patients diagnosed with non-small cell lung cancer (NSCLC) within the European Union. This enhancement aids pathologists in identifying NSCLC patients eligible for treatment with Libtayo, an anti-PD-1 immunotherapy designed to target cancer cells. PD-L1 IHC 22C3 pharmDx demonstrates the capability to detect NSCLC-treated patients with a tumor proportion score of 50% or higher, contributing to the development of immunohistochemistry-based diagnostics for cancer treatment.

End-user Segment Analysis

Based on end-user, the stem cell assay market is segmented into pharmaceutical & biotechnology companies, academic & research institutions, and contract research organizations (CROs). The pharmaceutical & biotechnology segment led the market in 2023, due to the rising demand for stem cell-based therapies and growing focus on drug discovery & development. In the drug delivery process, stem cells play a crucial role and they screen a large number of compounds. For instance,

• In July 2021, PerkinElmer, Inc., a renowned global leader dedicated to promoting a healthy world, introduced four new ready-to-use test kits for AlphaLISA KRAS. These kits are specifically designed to assist scientists in gaining a deeper understanding of the intricate protein structures and mutations associated with KRAS, facilitating the targeted identification of potential treatment options across various cancer types. Additionally, researchers have the flexibility to select between PerkinElmer's HTRF or AlphaLISA methods, enabling them to choose the most suitable approach for their laboratory experiments.

Regional Outlook

In terms of region, the global stem cell assay market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America held a major share of the market in 2023, due to the increasing investments in R&D, presence of pharmaceutical giants, and favorable government initiatives. Rising incidences of chronic diseases and increasing number of patients, and the availability of funding & grants that support the clinical research on stem cells are propelling the market in the region. For instance,

• In March 2021, Agilent Technologies Inc., a California, the US-based global provider of software, instrument, and laboratory services, disclosed its acquisition of Resolution Bioscience, a leading provider of next-generation sequencing-based precision oncology solutions. Under the terms of the agreement, Agilent provides Resolution Bioscience Inc. with USD 550 Million in cash, and an additional USD 145 Million contingent upon meeting predetermined performance milestones.  
  

  Get Free Sample Report